Takara Bio Beheer

Beheer criteriumcontroles 2/4

De CEO Takara Bio is Koichi Nakao, benoemd in May2009, heeft een ambtstermijn van 15.5 jaar. bezit rechtstreeks 0.061% van de aandelen van het bedrijf, ter waarde ¥ 74.28M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 5.4 jaar.

Belangrijke informatie

Koichi Nakao

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	15.5yrs
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	5.4yrs

Recente managementupdates

Recent updates

CEO

Koichi Nakao (62 yo)

15.5yrs

Tenure

Mr. Koichi Nakao was Director & President of Takara Bio Inc. from May 2009 to April 2020. Mr. Nakao was Director of Takara Bio Inc. from April 2002 to May 2009. He serves as Senior Managing Executive Offic...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Koichi Nakao	CEO, President & Representative Director	15.5yrs	geen gegevens	0.061% ¥ 74.3m
Yoh Hamaoka	CFO, Senior Executive Officer & Director	2.8yrs	geen gegevens	0.014% ¥ 17.1m
Takuya Kakemi	Executive Officer	no data	geen gegevens	geen gegevens
Akira Kodera	Managing Executive Officer & Head of Sales Division	1.8yrs	geen gegevens	geen gegevens
Noritaka Nishiwaki	Executive Officer	no data	geen gegevens	geen gegevens
Tsuyoshi Miyamura	Senior Managing Director & Director	10.4yrs	geen gegevens	0.011% ¥ 13.6m
Junichi Mineno	VP, Executive Officer & Director	2.8yrs	geen gegevens	0.012% ¥ 14.5m
Katsuhiko Kusakabe	CMCO, Senior Executive Officer & Director	7.4yrs	geen gegevens	0.0040% ¥ 4.8m
Andrew Farmer	Head of Research and Development	no data	geen gegevens	geen gegevens
Kyoko Nakajima	Managing Executive Officer & Head of SCM Division	1.8yrs	geen gegevens	geen gegevens
Ikuei Nukaya	Managing Executive Officer & Head of Quality Control Headquarters	less than a year	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4974 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Koichi Nakao	CEO, President & Representative Director	22.6yrs	geen gegevens	0.061% ¥ 74.3m
Yoh Hamaoka	CFO, Senior Executive Officer & Director	3.4yrs	geen gegevens	0.014% ¥ 17.1m
Tsuyoshi Miyamura	Senior Managing Director & Director	6.4yrs	geen gegevens	0.011% ¥ 13.6m
Junichi Mineno	VP, Executive Officer & Director	10.4yrs	geen gegevens	0.012% ¥ 14.5m
Katsuhiko Kusakabe	CMCO, Senior Executive Officer & Director	1.8yrs	geen gegevens	0.0040% ¥ 4.8m
Mutsumi Kimura	Director	2.4yrs	geen gegevens	0.043% ¥ 51.9m
Kazuko Kimura	Independent External Director	5.4yrs	geen gegevens	geen gegevens
Nobuko Kawashima	Independent External Director	8.4yrs	geen gegevens	geen gegevens
Yasuo Himeiwa	Independent Outside Audit & Supervisory Board Member	no data	geen gegevens	geen gegevens
Kunihiko Kamada	Independent Outside Audit & Supervisory Board Member	no data	geen gegevens	geen gegevens
Masaaki Makikawa	Independent Outside Audit & Supervisory Board Member	no data	geen gegevens	geen gegevens
Noriomi Matsumura	Independent External Director	4.4yrs	geen gegevens	geen gegevens

5.4yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4974 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).

Takara Bio Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Takara Bio Inc., Annual General Meeting, Jun 21, 2024

Takara Bio Inc., Annual General Meeting, Jun 23, 2023

Less than half of directors are independent

Takara Bio Inc., Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Recent updates

Takara Bio Inc. to Report Q2, 2025 Results on Nov 08, 2024

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 17%

Takara Bio Inc. to Report Q1, 2025 Results on Aug 08, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 21, 2024

Consensus EPS estimates fall by 30%

Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024

Consensus EPS estimates fall by 56%

Price target decreased by 17% to JP¥1,600

Upcoming dividend of JP¥17.00 per share

Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index (USD)

Takara Bio Inc. to Report Fiscal Year 2024 Results on May 10, 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 29%, revenue downgraded

Takara Bio Inc. to Report Q3, 2024 Results on Feb 14, 2024

Consensus EPS estimates fall by 15%

Price target decreased by 17% to JP¥1,933

Takara Bio Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Takara Bio Inc. to Report Q2, 2024 Results on Nov 09, 2023

Takara Bio Inc. to Report Q2, 2024 Results on Nov 14, 2023

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 16%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc. to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 23, 2023

Upcoming dividend of JP¥42.00 per share at 2.3% yield

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc. Provides Dividend Guidance for the Fiscal Year Ending Mar. 31, 2023

Takara Bio Inc. to Report Q3, 2023 Results on Feb 09, 2023

Price target decreased to JP¥2,250

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc. Provides Dividend Guidance for the Fiscal Year Ending Mar. 31, 2023

Takara Bio Inc. to Report Q2, 2023 Results on Nov 10, 2022

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to JP¥2,400

Takara Bio Inc. to Report Q1, 2023 Results on Aug 04, 2022

Price target decreased to JP¥2,515

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Takara Bio Inc. to Report Fiscal Year 2022 Results on May 12, 2022

Upcoming dividend of JP¥30.00 per share

Consensus revenue estimates increase by 16%

Price target decreased to JP¥2,742

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to JP¥2,792

Price target decreased to JP¥3,012

Second quarter 2022 earnings released: EPS JP¥33.09 (vs JP¥15.53 in 2Q 2021)

Consensus EPS estimates increase to JP¥91.00

First quarter 2022 earnings released: EPS JP¥50.04 (vs JP¥3.36 in 1Q 2021)

Takara Bio Inc. Provides Earnings Guidance for the Six Months Ending September 30, 2021; Provides Earnings Guidance for the Year Ending March 31, 2022

Full year 2021 earnings released: EPS JP¥79.28 (vs JP¥31.72 in FY 2020)

Upcoming dividend of JP¥14.00 per share

Takara Bio Inc. to Report Fiscal Year 2021 Results on May 13, 2021

Analysts increase EPS estimates to JP¥53.65

Third quarter 2021 earnings released: EPS JP¥28.67 (vs JP¥5.26 in 3Q 2020)

New 90-day high: JP¥3,045

New 90-day low: JP¥2,752

Takara Bio Inc. to Report Q3, 2021 Results on Feb 10, 2021

New 90-day high: JP¥3,020

Takara Bio Inc. to Report Q2, 2021 Results on Nov 10, 2020

CEO

Tenure

Leiderschapsteam